<DOC>
	<DOCNO>NCT00627120</DOCNO>
	<brief_summary>To assess safety tolerability single dose VGX-1027 range 1-800mg .</brief_summary>
	<brief_title>Phase I Safety Pharmacokinetic Study VGX-1027 Healthy Subjects</brief_title>
	<detailed_description>This study evaluate : - The safety tolerability single dose VGX-1027 determine : adverse event reporting , clinical laboratory result , vital sign , physical examination , electrocardiogram ( ECGs ) . - The pharmacokinetic ( PK ) profile VGX-1027 maximum concentration ( Cmax )</detailed_description>
	<criteria>Must give write informed consent . Healthy subject determine clinically significant deviation normal judge investigator medical history , physical examination , ECGs clinical laboratory evaluation Body Mass Index 1830kg/m^2 inclusive Males female age 1860 , inclusive . Women childbearing potential may enroll . Women must negative pregnancy test within 72 hour prior start study drug administration surgically sterile . Women childbearing potential Women pregnant breastfeed Women positive pregnancy test enrollment prior study drug administration Male subject unwilling agree practice barrier contraception study three month follow dose Any significant acute chronic mental illness Current recent gastrointestinal disease may impact absorption drug Any major surgery within 4 week enrollment Donation blood plasma blood bank clinical study ( except screen visit ) within 4 week enrollment Blood transfusion within 4 week enrollment Inability tolerate oral medication Inability venipunctured and/or tolerate venous access Recent ( within 6 month ) drug alcohol abuse History bleed disorder History head trauma seizures Any sound medical , psychiatric and/or social reason determine Investigator Evidence organ dysfunction clinically significant deviation normal vital sign , physical examination , ECG , clinical laboratory determination Positive urine screen drug abuse Positive blood screen hepatitis C antibody , hepatitis B surface antigen , HIV 1/2 antibody History significant drug allergy Exposure investigational drug within 4 week prior enrollment great 4 week investigational drug may longer halflife Use prescription drug counter acid controller within 4 week prior enrollment Use drug , include counter vitamin , medication and/or herbal preparation within 2 week prior enrollment Use oral , injectable implantable hormonal contraceptive agent within 3 month prior enrollment Use alcohol contain beverage within 1 week prior enrollment Use grapefruit containing product within 1 week prior enrollment Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g . infectious disease ) illness must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>healthy volunteer</keyword>
</DOC>